Zimmer Biomet (ZBH) Competitors

Zimmer Biomet (NYSE:ZBH) and Penumbra (NYSE:PEN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Which has stronger valuation and earnings, ZBH or PEN?

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$7.68B	2.43	$903.70M	$4.52	20.84
Penumbra	$1.19B	7.59	$14.01M	$1.06	220.98

Does the media favor ZBH or PEN?

In the previous week, Zimmer Biomet had 9 more articles in the media than Penumbra. MarketBeat recorded 17 mentions for Zimmer Biomet and 8 mentions for Penumbra. Zimmer Biomet's average media sentiment score of 0.65 beat Penumbra's score of 0.58 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate ZBH or PEN?

Zimmer Biomet presently has a consensus price target of $111.39, suggesting a potential upside of 18.25%. Penumbra has a consensus price target of $305.07, suggesting a potential upside of 30.24%. Given Penumbra's stronger consensus rating and higher probable upside, analysts plainly believe Penumbra is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35
Penumbra	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Is ZBH or PEN more profitable?

Zimmer Biomet has a net margin of 11.86% compared to Penumbra's net margin of 3.41%. Zimmer Biomet's return on equity of 12.73% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	11.86%	12.73%	7.34%
Penumbra	3.41%	11.14%	8.40%

Do institutionals and insiders have more ownership in ZBH or PEN?

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 0.7% of Zimmer Biomet shares are owned by company insiders. Comparatively, 5.0% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more volatility & risk, ZBH or PEN?

Zimmer Biomet has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Summary

Zimmer Biomet beats Penumbra on 9 of the 17 factors compared between the two stocks.